Key facts
- Tvaster Genkalp’s last known valuation is $7.4M (Apr 2025).
- It has raised $1.4M; the latest was Early Stage VC ($1.3M) in Apr 2025.
- Notable investors include Ideaspring Capital, Invigo Softwares, Mohamed Rela.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tvaster Genkalp
- ·The full record, as it builds
Funding rounds
No funding rounds for Tvaster Genkalp are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tvaster Genkalp
Developer of tumorigenesis blood-based epigenetic markers designed for cancer diagnostics. The company's markers use multiple advanced liquid biopsy methodologies to offer a screening test for hepatocellular carcinoma, enabling healthcare professionals to enhance early cancer detection and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Chennai, India
- Founded
- 2021
- Employees
- 8
- Website
- tvastergen.com/
- Ownership
- Privately Held (backing)
Tvaster Genkalp doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tvaster Genkalp shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tvaster Genkalp in its N-PORT filings yet. We sweep new filings monthly.